Evidence map›Paper›PMID 23894402›Full record

ArticlePloS one2013

Structural and functional perturbation of Giardia lamblia triosephosphate isomerase by modification of a non-catalytic, non-conserved region.

Gloria Hernández-Alcántara, Alfredo Torres-Larios, Sergio Enríquez-Flores, Itzhel García-Torres, Adriana Castillo-Villanueva, Sara T Méndez, Ignacio de la Mora-de la Mora, Saúl Gómez-Manzo, Angélica Torres-Arroyo, Gabriel López-Velázquez and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Benzimidazole Derivatives as New and Selective Inhibitors of Arginase fromInternational journal of molecular sciences · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential.International journal for parasitology. Drugs and drug resistance · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Treatment of giardiasis: current status and future directions.Current infectious disease reports · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Gloria Hernández-AlcántaraLaboratorio de Bioquímica-Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City, Mexico.
Alfredo Torres-Larios
Sergio Enríquez-Flores
Itzhel García-Torres
Adriana Castillo-Villanueva
Sara T Méndez
Ignacio de la Mora-de la Mora
Saúl Gómez-Manzo
Angélica Torres-Arroyo
Gabriel López-Velázquez
Horacio Reyes-Vivas
Jesús Oria-Hernández
Secretaria de Salud · MXInstituto Nacional de Pediatria · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe have previously proposed triosephosphate isomerase of Giardia lamblia (GlTIM) as a target for rational drug design against giardiasis, one of the most common parasitic infections in humans. Since the enzyme exists in the parasite and the host, selective inhibition is a major challenge because essential regions that could be considered molecular targets are highly conserved. Previous biochemical evidence showed that chemical modification of the non-conserved non-catalytic cysteine 222 (C222) inactivates specifically GlTIM. The inactivation correlates with the physicochemical properties of the modifying agent: addition of a non-polar, small chemical group at C222 reduces the enzyme activity by one half, whereas negatively charged, large chemical groups cause full inactivation.

resultsIn this work we used mutagenesis to extend our understanding of the functional and structural effects triggered by modification of C222. To this end, six GlTIM C222 mutants with side chains having diverse physicochemical characteristics were characterized. We found that the polarity, charge and volume of the side chain in the mutant amino acid differentially alter the activity, the affinity, the stability and the structure of the enzyme. The data show that mutagenesis of C222 mimics the effects of chemical modification. The crystallographic structure of C222D GlTIM shows the disruptive effects of introducing a negative charge at position 222: the mutation perturbs loop 7, a region of the enzyme whose interactions with the catalytic loop 6 are essential for TIM stability, ligand binding and catalysis. The amino acid sequence of TIM in phylogenetic diverse groups indicates that C222 and its surrounding residues are poorly conserved, supporting the proposal that this region is a good target for specific drug design.

conclusionsThe results demonstrate that it is possible to inhibit species-specifically a ubiquitous, structurally highly conserved enzyme by modification of a non-conserved, non-catalytic residue through long-range perturbation of essential regions.

Indexed as

Mutagenesis, Site-DirectedBiocatalysisConserved SequenceCrystallography, X-RayEnzyme StabilityGiardia lambliaGlycolatesKineticsModels, MolecularMutationProtein ConformationRecombinant ProteinsSpectrum AnalysisTriose-Phosphate IsomeraseGlycolatesphosphoglycolateRecombinant ProteinsTriose-Phosphate Isomerase

Identifiers

PMID23894402
PMCPMC3718800
OpenAlexW2030022891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.